BioArctic AB 2018 AR2
The report highlights BioArctic's successful year in 2018, marked by positive Phase 2b study results for its Alzheimer's drug candidate BAN2401 and the outlicensing of its Parkinson's antibody portfolio to AbbVie, which triggered a MUSD 50 milestone payment. The company also progressed its spinal cord injury project, SC0806, into the next panel of its Phase 1/2 study. Financially, BioArctic experienced significant growth, with net revenues increasing to MSEK 714.0 and operating profit rising to MSEK 488.8. On the sustainability front, the company was recognized with a shared second place in the 2018 Allbright Award for its achievements in gender equality.
Company: BioArctic AB
Sector: Professional & technical services
Country: Sweden
Year: 2018
Type: AR2
Pages: 98
Back to company
BioArctic AB
Annual Report
The report highlights BioArctic's successful year in 2018, marked by positive Phase 2b study results for its Alzheimer's drug candidate BAN2401 and the outlicensing of its Parkinson's antibody portfolio to AbbVie, which triggered a MUSD 50 milestone payment. The company also progressed its spinal cord injury project, SC0806, into the next panel of its Phase 1/2 study. Financially, BioArctic experienced significant growth, with net revenues increasing to MSEK 714.0 and operating profit rising to MSEK 488.8. On the sustainability front, the company was recognized with a shared second place in the 2018 Allbright Award for its achievements in gender equality.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees